SCHEMBL14980327

SCHEMBL14980327

CN1CCC(Nc2ccnc3ccccc23)CC1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 1/20 0.59
DYRK1B Q9Y463 1/20 0.59
ADRA2A P08913 1/20 0.54
ADRA2B P18089 1/20 0.54
ADRA2C P18825 1/20 0.54
KDM4E B2RXH2 1/20 0.51
MEN1 O00255 1/20 0.51
ALDH1A1 P00352 1/20 0.51
KMT2A Q03164 1/20 0.51
HRH3 Q9Y5N1 5/20 0.48
KMT5B Q4FZB7 2/20 0.47
KMT5C Q86Y97 2/20 0.47
HTR1A P08908 2/20 0.47
ADRA1D P25100 2/20 0.47
ADRA1A P35348 2/20 0.47
ADRA1B P35368 2/20 0.47
HTR2C P28335 1/20 0.46
HTR2B P41595 1/20 0.46
RET P07949 1/20 0.45
CYP2D6 P10635 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5393762 0.86 HTR1A (0.56) KDM4EMEN1ALDH1A1KMT2AHRH3
SCHEMBL16219448 0.85 KDM4E (0.48) DYRK1ADYRK1BADRA2AADRA2BADRA2C
SCHEMBL19464787 0.85 WHR1 (0.56) DYRK1ADYRK1BADRA2AADRA2BADRA2C
SCHEMBL15191123 0.82 KDM4E (0.52) DYRK1ADYRK1BKDM4EMEN1ALDH1A1
SCHEMBL30307410 0.82 KMT5B (0.62) KDM4EHRH3KMT5BKMT5CHTR1A
SCHEMBL20292863 0.81 DYRK1A (0.58) DYRK1ADYRK1BKDM4EMEN1ALDH1A1
SCHEMBL15190761 0.80 ADRA2A (0.47) DYRK1ADYRK1BADRA2AADRA2BADRA2C
SCHEMBL12634152 0.79 KMT5B (0.49) ALDH1A1HRH3KMT5BKMT5CHTR1A
Hydrochloric Acid SCHEMBL23360249 0.78 KMT5B (0.48) ALDH1A1HRH3KMT5BKMT5CHTR1A
Hydrochloric Acid SCHEMBL29862886 0.78 KMT5B (0.48) ALDH1A1HRH3KMT5BKMT5CHTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9790499-B2 Functionally-modified oligonucleotides and subunits thereof SAREPTA THERAPEUTICS, INC. (US) 2017-10-17 US disclosed
US-9278987-B2 Functionally-modified oligonucleotides and subunits thereof SAREPTA THERAPEUTICS, INC. (US) 2016-03-08 US disclosed
US-20140330006-A1 FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF SAREPTA THERAPEUTICS, INC. (US) 2014-11-06 US disclosed
WO-2013074834-A1 FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF SAREPTA THERAPEUTICS, INC. (US) 2013-05-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140330006-A1 FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF RTCB, NSUN3, NSUN2 DYRK1A 4502/4885DYRK1B 4456/4885ADRA2A 4714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.